YAAS Overview

Warrant Exercise Announcement: Youxin Technology Ltd has raised approximately $4.48 million from the exercise of warrants, resulting in the issuance of 1,752,134 Class A ordinary shares, with a significant percentage of both Series A and B warrants exercised.

Financial Strengthening: The Chairman of Youxin Technology expressed satisfaction with the cash infusion from the warrant exercises, which will support new business opportunities and strategic growth objectives.

Company Overview: Youxin Technology is a SaaS and PaaS provider focused on helping retail enterprises digitally transform their operations through cloud-based solutions that integrate various aspects of commerce.

Forward-Looking Statements: The press release includes forward-looking statements regarding the company's future product development and business prospects, emphasizing that actual results may differ due to various risks and uncertainties.

Regaining Compliance: Youxin Technology (YAAS) announced that it has been informed by Nasdaq that the company has regained compliance with listing requirements.

Market Impact: This development may positively influence investor confidence and the company's stock performance on the Nasdaq exchange.

Regaining Compliance: Youxin Technology Ltd has received confirmation from Nasdaq that it has regained compliance with the stockholders' equity rule, having demonstrated stockholders' equity exceeding $2.5 million.

Previous Non-Compliance: The company was previously notified on August 13, 2025, of its non-compliance with Nasdaq's minimum requirements, which include stockholders' equity, market value of listed securities, and net income from continuing operations.

Merus Acquisition: Merus NV shares surged 38.2% to $95.21 following Genmab's announcement of an $8 billion all-cash acquisition, which includes the breakthrough therapy Petosemtamab.

Pre-Market Gainers: Notable pre-market gainers included Steakholder Foods (up 92%), JFB Construction Holdings (up 77.4%), and Plus Therapeutics (up 24.3%), among others.

Pre-Market Losers: MoonLake Immunotherapeutics saw a significant drop of 86.3% after disappointing trial results, while Maris Tech and Sunrise New Energy also experienced substantial declines.

Market Overview: The article provides a snapshot of various stocks' performances in pre-market trading, highlighting both significant gainers and losers.

Delisting Notice: Youxin Technology received a delisting notice from Nasdaq on September 22, 2025, due to its Class A ordinary shares closing bid price falling below $0.10 for 10 consecutive trading days.

Share Consolidation: To regain compliance with Nasdaq's minimum bid price requirement, the company approved a share consolidation at a ratio of 1:80, effective September 30, 2025, reducing the number of outstanding shares significantly.